Polar Capital Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Polar Capital Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-350,000	Closed	-$31M	–	284
2023 Q3	$31M	Sell	350,000 -75,000	-18%	-$6.67M	0.23%	110
2023 Q2	$36.8M	Hold	425,000	–	–	0.19%	104
2023 Q1	$41.3M	Buy	425,000 +250,000	+143%	+$25.9M	0.27%	94
2022 Q4	$18.1M	Sell	175,000 -50,000	-22%	-$4.69M	0.14%	154
2022 Q3	$19.1K	Hold	225,000	–	–	0.12%	147
2022 Q2	$18.6K	Sell	225,000 -275,000	-55%	-$21.9M	0.11%	150
2022 Q1	$38.5K	Buy	500,000 +375,000	+300%	+$31.4M	0.17%	105
2021 Q4	$11K	Hold	125,000	–	–	0.04%	223
2021 Q3	$9.66K	Hold	125,000	–	–	0.04%	235
2021 Q2	$10.4K	Hold	125,000	–	–	0.05%	221
2021 Q1	$9.44M	Sell	125,000 -225,000	-64%	-$18.4M	0.06%	212
2020 Q4	$30.7M	Buy	+350,000	New	+$27.7M	0.19%	120

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Polar Capital Holdings's BMRN Position: Q4 2023 in Review

Polar Capital Holdings sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 350,000 shares — an estimated $31M sold.

Polar Capital Holdings first reported a position in BMRN in Q4 2020 and held it in 12 quarters. The position peaked at $41.3M in Q1 2023. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

Polar Capital Holdings reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Polar Capital Holdings sold 350,000 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $31M.
Polar Capital Holdings first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 12 quarters.
Polar Capital Holdings's BioMarin Pharmaceuticals position peaked at $41.3M in Q1 2023.
547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Polar Capital Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.